Andrew J. Murphy

Andrew J. Murphy

Auto-generated profile, based on publicly available information

Andrew J. Murphy

Regeneron Pharmaceuticals, Tarrytown, USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2007 in Science
Verified
Journal Article
Closed access
PDF file
TTTo-Ha Thai
To-Ha Thai
DCDinis Pedro Calado
Dinis Pedro Calado
SCStefano Casola
Stefano Casola
KAK. Mark Ansel
K. Mark Ansel
CXChangchun Xiao
Changchun Xiao
KRKlaus Rajewsky
Klaus Rajewsky
MicroRNAs are small RNA species involved in biological control at multiple levels. Using genetic deletion and transgenic approaches, we show that the evolutionarily conserved microRNA-155 (miR-155) has an important role in the mammalian immune system, specifically in regulating T helper cell differentiation and the germinal center reaction to produce an optimal T cell–dependent antibody response. miR-155 exerts this control, at least in part, by regulating cytokine production. These results also suggest that individual microRNAs can exert critical control over mammalian differentiation processes in vivo.

21 August 2020 in Science
Verified
Journal Article
Open access
PDF file
ABAlina Baum
Alina Baum
BFBenjamin O. Fulton
Benjamin O. Fulton
EWElzbieta Wloga
Elzbieta Wloga
RCRichard Copin
Richard Copin
KPKristen E. Pascal
Kristen E. Pascal
CKChristos A. Kyratsous
Christos A. Kyratsous
An antibody cocktail against SARS-CoV-2: There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated a large panel of antibodies against the spike protein from humanized mice and recovered patients. From this panel, they identified several neutralizing antibodies, including pairs that do not compete for binding to the receptor binding domain. Baum et al. focused in on four of these antibodies. All four are effective against known spike variants. However, by growing a pseudovirus that expresses the spike in the presence of individual antibodies, the authors were able to select for spike mutants resistant to that antibody. In contrast, escape mutants are not selected when pseudovirus is grown in the presence of pairs of antibodies that either do not compete or only partially compete for binding to the RBD. Such a pair might be used in a therapeutic antibody cocktail. Science , this issue p. 1010 , p. 1014

21 August 2020 in Science
Verified
Journal Article
Open access
PDF file
JHJohanna Hansen
Johanna Hansen
ABAlina Baum
Alina Baum
KPKristen E. Pascal
Kristen E. Pascal
VRVincenzo Russo
Vincenzo Russo
SGStephanie Giordano
Stephanie Giordano
CKChristos A. Kyratsous
Christos A. Kyratsous
An antibody cocktail against SARS-CoV-2: There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated a large panel of antibodies against the spike protein from humanized mice and recovered patients. From this panel, they identified several neutralizing antibodies, including pairs that do not compete for binding to the receptor binding domain. Baum et al. focused in on four of these antibodies. All four are effective against known spike variants. However, by growing a pseudovirus that expresses the spike in the presence of individual antibodies, the authors were able to select for spike mutants resistant to that antibody. In contrast, escape mutants are not selected when pseudovirus is grown in the presence of pairs of antibodies that either do not compete or only partially compete for binding to the RBD. Such a pair might be used in a therapeutic antibody cocktail. Science , this issue p. 1010 , p. 1014

1 December 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
DLDavid B. Lombard
David B. Lombard
FAFrederick W. Alt
Frederick W. Alt
HCHwei-Ling Cheng
Hwei-Ling Cheng
JBJakob Bunkenborg
Jakob Bunkenborg
RSRyan S. Streeper
Ryan S. Streeper
BSBjoern Schwer
Bjoern Schwer
Homologs of the Saccharomyces cerevisiae Sir2 protein, sirtuins, promote longevity in many organisms. Studies of the sirtuin SIRT3 have so far been limited to cell culture systems. Here, we investigate the localization and function of SIRT3 in vivo. We show that endogenous mouse SIRT3 is a soluble mitochondrial protein. To address the function and relevance of SIRT3 in the regulation of energy metabolism, we generated and phenotypically characterized SIRT3 knockout mice. SIRT3-deficient animals exhibit striking mitochondrial protein hyperacetylation, suggesting that SIRT3 is a major mitochondrial deacetylase. In contrast, no mitochondrial hyperacetylation was detectable in mice lacking the two other mitochondrial sirtuins, SIRT4 and SIRT5. Surprisingly, despite this biochemical phenotype, SIRT3-deficient mice are metabolically unremarkable under basal conditions and show normal adaptive thermogenesis, a process previously suggested to involve SIRT3. Overall, our results extend the recent finding of lysine acetylation of mitochondrial proteins and demonstrate that SIRT3 has evolved to control reversible lysine acetylation in this organelle.

1 September 2006 in Cell
Verified
Journal Article
Closed access
MHMarcia C. Haigis
Marcia C. Haigis
RMRaul Mostoslavsky
Raul Mostoslavsky
KHKevin M. Haigis
Kevin M. Haigis
KFKamau Fahie
Kamau Fahie
DCDanos C. Christodoulou
Danos C. Christodoulou
LGLeonard Guarente
Leonard Guarente

1 December 2008 in Immunity
Verified
Journal Article
Closed access
LZLauren A. Zenewicz
Lauren A. Zenewicz
GYGeorge D. Yancopoulos
George D. Yancopoulos
DVDavid M. Valenzuela
David M. Valenzuela
AMAndrew J. Murphy
Andrew J. Murphy
SSSean Stevens
Sean Stevens
RFRichard A. Flavell
Richard A. Flavell